ECD for islet transplantation

Takashi Kenmochi, Takehide Asano, Naotake Akutsu, Taihei Ito

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pancreatic islet transplantation offers a minimally invasive option for type 1 diabetic patients. Before 2000, less than 10 % of the recipients of islet transplantation achieved insulin independency [1]. The introduction of the Edmonton Protocol, however, with a highly improved rate of insulin independency, encouraged us to promote clinical islet transplantation [2, 3]. In the Edmonton Protocol, brain-dead donors were used for islet isolation, and the donors were selected according to the factors that influence the success of islet isolation [4]. Even using the Edmonton Protocol, the results of clinical islet transplantation including a long-term graft survival were far from ideal and were significantly worse than clinical pancreas transplantation (pancreas transplant alone, PTA). The newly designed protocol from Minnesota University by Hering et al. that includes induction therapy with a T-cell-depleting antibody (anti-thymus globulin, ATG) and an inhibitor of tumor necrosis factor-α (TNF-α) achieved successful islet transplantation from a single donor. Short-term and long-term islet graft survivals were shown which were comparable to those in clinical pancreas transplantation (PTA). These results demonstrated that islet transplantation was expected to take the place of solitary pancreas transplantation for the type 1 diabetic patients without renal dysfunction. Strict donor criteria are not necessarily needed for islet transplantation because the islets were transplanted after its evaluation after isolation, which is different from pancreas transplantation in which the pancreas is transplanted to the recipients immediately after procurement from the donor. Therefore, extended criteria donor has not been clearly defined in islet transplantation. DBD donors were most frequently used for islet transplantation worldwide. In our country, however, DCD donors were used for islet transplantation because of an ultimate shortage of DBD donors and the regulation under Organ Transplantation Law that was enforced in 1997. Although a clear definition as an extended criteria donor for islet transplantation has not been determined, the factors that influence the outcome of the islet isolation were investigated in previous papers. In this chapter, the factors that influence the outcome of the islet isolation were introduced and extended criteria donor for islet transplantation is discussed.

Original languageEnglish
Title of host publicationMarginal Donors
Subtitle of host publicationCurrent and Future Status
PublisherSpringer Japan
Pages249-256
Number of pages8
ISBN (Electronic)9784431544845
ISBN (Print)4431544836, 9784431544838
DOIs
Publication statusPublished - 01-12-2013

Fingerprint

Islets of Langerhans Transplantation
Tissue Donors
Pancreas Transplantation
Graft Survival
Pancreas
Insulin
Brain Death
Globulins
Organ Transplantation
Clinical Protocols
Thymus Gland
Anti-Idiotypic Antibodies
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kenmochi, T., Asano, T., Akutsu, N., & Ito, T. (2013). ECD for islet transplantation. In Marginal Donors: Current and Future Status (pp. 249-256). Springer Japan. https://doi.org/10.1007/978-4-431-54484-5_22
Kenmochi, Takashi ; Asano, Takehide ; Akutsu, Naotake ; Ito, Taihei. / ECD for islet transplantation. Marginal Donors: Current and Future Status. Springer Japan, 2013. pp. 249-256
@inbook{3a504f365a2c4bbc9242bf585d02a4b7,
title = "ECD for islet transplantation",
abstract = "Pancreatic islet transplantation offers a minimally invasive option for type 1 diabetic patients. Before 2000, less than 10 {\%} of the recipients of islet transplantation achieved insulin independency [1]. The introduction of the Edmonton Protocol, however, with a highly improved rate of insulin independency, encouraged us to promote clinical islet transplantation [2, 3]. In the Edmonton Protocol, brain-dead donors were used for islet isolation, and the donors were selected according to the factors that influence the success of islet isolation [4]. Even using the Edmonton Protocol, the results of clinical islet transplantation including a long-term graft survival were far from ideal and were significantly worse than clinical pancreas transplantation (pancreas transplant alone, PTA). The newly designed protocol from Minnesota University by Hering et al. that includes induction therapy with a T-cell-depleting antibody (anti-thymus globulin, ATG) and an inhibitor of tumor necrosis factor-α (TNF-α) achieved successful islet transplantation from a single donor. Short-term and long-term islet graft survivals were shown which were comparable to those in clinical pancreas transplantation (PTA). These results demonstrated that islet transplantation was expected to take the place of solitary pancreas transplantation for the type 1 diabetic patients without renal dysfunction. Strict donor criteria are not necessarily needed for islet transplantation because the islets were transplanted after its evaluation after isolation, which is different from pancreas transplantation in which the pancreas is transplanted to the recipients immediately after procurement from the donor. Therefore, extended criteria donor has not been clearly defined in islet transplantation. DBD donors were most frequently used for islet transplantation worldwide. In our country, however, DCD donors were used for islet transplantation because of an ultimate shortage of DBD donors and the regulation under Organ Transplantation Law that was enforced in 1997. Although a clear definition as an extended criteria donor for islet transplantation has not been determined, the factors that influence the outcome of the islet isolation were investigated in previous papers. In this chapter, the factors that influence the outcome of the islet isolation were introduced and extended criteria donor for islet transplantation is discussed.",
author = "Takashi Kenmochi and Takehide Asano and Naotake Akutsu and Taihei Ito",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/978-4-431-54484-5_22",
language = "English",
isbn = "4431544836",
pages = "249--256",
booktitle = "Marginal Donors",
publisher = "Springer Japan",
address = "Japan",

}

Kenmochi, T, Asano, T, Akutsu, N & Ito, T 2013, ECD for islet transplantation. in Marginal Donors: Current and Future Status. Springer Japan, pp. 249-256. https://doi.org/10.1007/978-4-431-54484-5_22

ECD for islet transplantation. / Kenmochi, Takashi; Asano, Takehide; Akutsu, Naotake; Ito, Taihei.

Marginal Donors: Current and Future Status. Springer Japan, 2013. p. 249-256.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - ECD for islet transplantation

AU - Kenmochi, Takashi

AU - Asano, Takehide

AU - Akutsu, Naotake

AU - Ito, Taihei

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Pancreatic islet transplantation offers a minimally invasive option for type 1 diabetic patients. Before 2000, less than 10 % of the recipients of islet transplantation achieved insulin independency [1]. The introduction of the Edmonton Protocol, however, with a highly improved rate of insulin independency, encouraged us to promote clinical islet transplantation [2, 3]. In the Edmonton Protocol, brain-dead donors were used for islet isolation, and the donors were selected according to the factors that influence the success of islet isolation [4]. Even using the Edmonton Protocol, the results of clinical islet transplantation including a long-term graft survival were far from ideal and were significantly worse than clinical pancreas transplantation (pancreas transplant alone, PTA). The newly designed protocol from Minnesota University by Hering et al. that includes induction therapy with a T-cell-depleting antibody (anti-thymus globulin, ATG) and an inhibitor of tumor necrosis factor-α (TNF-α) achieved successful islet transplantation from a single donor. Short-term and long-term islet graft survivals were shown which were comparable to those in clinical pancreas transplantation (PTA). These results demonstrated that islet transplantation was expected to take the place of solitary pancreas transplantation for the type 1 diabetic patients without renal dysfunction. Strict donor criteria are not necessarily needed for islet transplantation because the islets were transplanted after its evaluation after isolation, which is different from pancreas transplantation in which the pancreas is transplanted to the recipients immediately after procurement from the donor. Therefore, extended criteria donor has not been clearly defined in islet transplantation. DBD donors were most frequently used for islet transplantation worldwide. In our country, however, DCD donors were used for islet transplantation because of an ultimate shortage of DBD donors and the regulation under Organ Transplantation Law that was enforced in 1997. Although a clear definition as an extended criteria donor for islet transplantation has not been determined, the factors that influence the outcome of the islet isolation were investigated in previous papers. In this chapter, the factors that influence the outcome of the islet isolation were introduced and extended criteria donor for islet transplantation is discussed.

AB - Pancreatic islet transplantation offers a minimally invasive option for type 1 diabetic patients. Before 2000, less than 10 % of the recipients of islet transplantation achieved insulin independency [1]. The introduction of the Edmonton Protocol, however, with a highly improved rate of insulin independency, encouraged us to promote clinical islet transplantation [2, 3]. In the Edmonton Protocol, brain-dead donors were used for islet isolation, and the donors were selected according to the factors that influence the success of islet isolation [4]. Even using the Edmonton Protocol, the results of clinical islet transplantation including a long-term graft survival were far from ideal and were significantly worse than clinical pancreas transplantation (pancreas transplant alone, PTA). The newly designed protocol from Minnesota University by Hering et al. that includes induction therapy with a T-cell-depleting antibody (anti-thymus globulin, ATG) and an inhibitor of tumor necrosis factor-α (TNF-α) achieved successful islet transplantation from a single donor. Short-term and long-term islet graft survivals were shown which were comparable to those in clinical pancreas transplantation (PTA). These results demonstrated that islet transplantation was expected to take the place of solitary pancreas transplantation for the type 1 diabetic patients without renal dysfunction. Strict donor criteria are not necessarily needed for islet transplantation because the islets were transplanted after its evaluation after isolation, which is different from pancreas transplantation in which the pancreas is transplanted to the recipients immediately after procurement from the donor. Therefore, extended criteria donor has not been clearly defined in islet transplantation. DBD donors were most frequently used for islet transplantation worldwide. In our country, however, DCD donors were used for islet transplantation because of an ultimate shortage of DBD donors and the regulation under Organ Transplantation Law that was enforced in 1997. Although a clear definition as an extended criteria donor for islet transplantation has not been determined, the factors that influence the outcome of the islet isolation were investigated in previous papers. In this chapter, the factors that influence the outcome of the islet isolation were introduced and extended criteria donor for islet transplantation is discussed.

UR - http://www.scopus.com/inward/record.url?scp=84930687805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930687805&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-54484-5_22

DO - 10.1007/978-4-431-54484-5_22

M3 - Chapter

SN - 4431544836

SN - 9784431544838

SP - 249

EP - 256

BT - Marginal Donors

PB - Springer Japan

ER -

Kenmochi T, Asano T, Akutsu N, Ito T. ECD for islet transplantation. In Marginal Donors: Current and Future Status. Springer Japan. 2013. p. 249-256 https://doi.org/10.1007/978-4-431-54484-5_22